NCT07818005Completed
Retrospective Continuous Glucose Monitor (CGM) Study on Glycemic Response and Body Composition in College Students
A Retrospective Study of Individual Glycemic Response Based on CGM Wearable Devices in Weight and Body Composition Management Among College Students
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
This retrospective study evaluates the real-world effect of individualized glycemic response-guided dietary management, based on continuous glucose monitoring (CGM), on weight and body composition in overweight and obese university students. All data for this analysis were retrospectively retrieved from the archived records of a randomized controlled trial conducted at He University, in which 60 students (body mass index \[BMI\] ≥ 24 kg/m² or elevated body fat percentage) had worn CGM sensors for 4 weeks. The archived records show that the exposed group (n = 30) had received individualized dietary guidance generated from their own glucose responses, including structured CGM reports, meal composition and eating-order advice, and standardized feedback, whereas the non-exposed group (n = 30) had worn CGM without receiving any dietary guidance. One non-exposed participant was excluded from this retrospective analysis for missing primary outcome data, leaving 59 participants for analysis. The archived dataset contains body composition (weight, body mass index \[BMI\], body fat mass, percent body fat, skeletal muscle mass, visceral fat level) and eating behavior records at Day 0, Day 28, and Day 90. This analysis examines whether the 4-week intervention produced sustained, fat-mass-driven improvements in body composition and whether changes in eating behavior mediated these effects.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 59 (actual)
- First submitted
- 25 Aug 2026
- Start date
- 27 Jun 2026
- Primary completion date
- 30 Jul 2026
- Lead sponsor
- He Eye Hospital
- Diseases
- Obesity
- NCT number
- NCT07818005
What you commit to
- Study type: Observational
- Participants enrolled: 59
- From 27 Jun 2026 to the primary completion date, 30 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Weight gain or glycemic abnormality induced by medications (e.g., glucocorticoids, antipsychotics, insulin secretagogues)
- Diagnosed dyslipidemia with lipid-lowering medication
Other illness
- Polycystic ovary syndrome (PCOS)
- High risk of eating disorders identified by the Eating Disorder Diagnostic Scale (EDDS)
- Severe psychiatric disorders or psychotropic medication use
- Allergy to CGM adhesive or hydrogel, or active skin disease affecting sensor wear
Lab values
- Diagnosed diabetes (type 1 or type 2) or prediabetes (fasting glucose ≥ 6.1 mmol/L or glycated hemoglobin (HbA1c)≥ 5.7%)
Other
- Pregnancy, lactation, or planned pregnancy within 6 months
- Professional athletes (high-intensity physical activity ≥ 5 times/week, ≥ 60 min/session)
- Weight change \> 5% of initial body weight within the past 3 months
- Participation in other commercial or clinical weight-loss programs
Who the study is looking for
- University students aged 18 to 25 years
- Body mass index (BMI) ≥ 24.0 kg/m², or body fat percentage ≥ 25% (male) / ≥ 32% (female)
- Self-reported presence of at least two unhealthy eating behaviors
- Written informed consent
Age in the registry: 18 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| He University, Shenyang, Liaoning, China Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.